Kardigan targets $1.4 billion valuation in U.S. IPO
Full article text is available in the Catalayer news terminal.
Summary
Princeton-based clinical-stage biotech Kardigan filed for a US IPO targeting a valuation of up to $1.4 billion, offering 23.3 million shares at $14-16 for gross proceeds potentially reaching $373.3 million, to fund three late-stage cardiovascular programs through 2028 as the biotech IPO market shows signs of renewed activity.
Market Impact
Kardigan's IPO reflects reviving biotech capital markets, arriving a day after Parabilis Medicines raised $670 million in what was called the largest biotech IPO in history. At a $15 midpoint, Kardigan expects to raise about $320.3 million (up to $369.1 million with the over-allotment), giving a market value around $1.37 billion. The company is advancing three late-stage cardiovascular candidates—danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension—with R&D spending surging to $45.1 million in Q1, more than double the prior year, as clinical activity intensified. Shares will trade on Nasdaq as 'KARD' with J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen managing the offering.
Why It Matters
Kardigan's $1.4 billion IPO target, following a record biotech listing, signals renewed investor appetite for clinical-stage biotech, reopening capital markets for late-stage drug developers after a prolonged drought.
Key Points
- Kardigan filed for a US IPO targeting a valuation of up to $1.4 billion, offering 23.3 million shares at $14-16 for gross proceeds potentially reaching $373.3 million
- The company is advancing three late-stage cardiovascular programs: danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension
- R&D spending surged to $45.1 million in Q1, more than double the year-ago figure; proceeds plus current cash are expected to fund the company through 2028
- Shares will trade on Nasdaq as 'KARD'; the IPO arrives a day after Parabilis Medicines raised $670 million in what Fierce Biotech called the largest biotech IPO in history
Key Entities
Evidence
Kardigan filed for a U.S. initial public offering targeting a valuation of up to $1.4 billion, the Princeton, New Jersey-based clinical-stage biotech said on Thursday. Its offering consists of 23.3 million shares in a...Supports: Confirms the IPO valuation target, share count, and price range
Kardigan is focusing on three late-stage cardiovascular programs: danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen, which is being tested for acute severe hy...Supports: Documents the three cardiovascular programs
Parabilis Medicines, which raised $670 million in what Fierce Biotech called the largest IPO in biotech history, began trading on Nasdaq the day before Kardigan's announcementSupports: Grounds the reviving biotech IPO market context